Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining more than 300…
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday’s session following third-quarter results. Jabil reported third-quarter fiscal 2024…
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Molecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday’s regular session. The market value of their…
Gold Rises 1%; Accenture Shares Surge After Q3 Results
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 50 points on Thursday.…
Deep Dive Into Femasys Stock: Analyst Perspectives (4 Ratings)
In the preceding three months, 4 analysts have released ratings for Femasys (NASDAQ:FEMY), presenting a wide array of…
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says
Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Trxade Health (NASDAQ:MEDS) stock rose 105.3% to $8.5 during Monday’s after-market session. The company’s market cap stands…
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Syra Health (NASDAQ:SYRA) shares rose 479.7% to $6.44 during Thursday’s regular session. The company’s market cap stands…
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers ThermoGenesis Holdings (NASDAQ:THMO) stock moved upwards by 39.0% to $0.86 during Wednesday’s regular session. The market value…
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment At Stanford Medicine; FemBloc Is Being Developed As A First- Of-Its-Kind, Non-Surgical Permanent Birth Control With A Clearly Defined U.S. Regulatory Pathway
- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second academic center to participate in the FemBloc pivotal trial since enrollment began last